118 related articles for article (PubMed ID: 1959847)
1. Colchicine clearance is impaired in alcoholic cirrhosis.
Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects.
Mazoit JX; Sandouk P; Zetlaoui P; Scherrmann JM
Anesth Analg; 1987 Apr; 66(4):293-8. PubMed ID: 3565791
[TBL] [Abstract][Full Text] [Related]
3. Serum leptin levels in alcoholic liver cirrhosis: relationship with gender, nutritional status, liver function and energy metabolism.
Campillo B; Sherman E; Richardet JP; Bories PN
Eur J Clin Nutr; 2001 Nov; 55(11):980-8. PubMed ID: 11641747
[TBL] [Abstract][Full Text] [Related]
4. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
Wensing G; Hoffmann K; Heidemann HT
Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cimetidine in patients with liver disease.
González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
[TBL] [Abstract][Full Text] [Related]
6. Half-life time or clearance of indocyanine green in patients with liver disease.
Gilmore IT; Marigold JH; Thompson RP
Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
[TBL] [Abstract][Full Text] [Related]
7. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
[TBL] [Abstract][Full Text] [Related]
8. Sufentanil pharmacokinetics in patients with cirrhosis.
Chauvin M; Ferrier C; Haberer JP; Spielvogel C; Lebrault C; Levron JC; Duvaldestin P
Anesth Analg; 1989 Jan; 68(1):1-4. PubMed ID: 2521279
[TBL] [Abstract][Full Text] [Related]
9. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of famotidine after intravenous administration in liver disease.
Ohnishi K
Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
[TBL] [Abstract][Full Text] [Related]
11. Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal.
Henriksen JH; Holst JJ; Møller S; Brinch K; Bendtsen F
Hepatology; 1999 Jun; 29(6):1818-24. PubMed ID: 10347125
[TBL] [Abstract][Full Text] [Related]
12. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
Morgan MY; Stambuk D
Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
[TBL] [Abstract][Full Text] [Related]
13. Furosemide disposition in cirrhotic patients.
Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis.
D'Honneur G; Khalil M; Dominique C; Haberer JP; Kleef UW; Duvaldestin P
Anesth Analg; 1993 Dec; 77(6):1203-6. PubMed ID: 8250313
[TBL] [Abstract][Full Text] [Related]
15. Ranitidine disposition in severe hepatic cirrhosis.
Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucose on hepatic conversion of aminonitrogen to urea in patients with cirrhosis: relationship to glucagon.
Hamberg O; Vilstrup H
Hepatology; 1994 Jan; 19(1):45-54. PubMed ID: 7903954
[TBL] [Abstract][Full Text] [Related]
17. Fasting plasma somatostatin in alcoholic liver disease.
Kelbaek H; Tronier B; Bahnsen M; Munkgaard S; Pedersen H
Scand J Clin Lab Invest; 1983 Nov; 43(7):597-601. PubMed ID: 6140748
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
[TBL] [Abstract][Full Text] [Related]
19. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis.
Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J
Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169
[TBL] [Abstract][Full Text] [Related]
20. Quinidine disposition in relation to antipyrine elimination and debrisoquine phenotype in alcoholic patients with and without cirrhosis.
Debruyne D; Gram LF; Grollier G; Camsonne R; Agron L; Dao MT; Lacotte J; Bigot MC; Moulin M
Int J Clin Pharmacol Res; 1989; 9(5):319-25. PubMed ID: 2625371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
